Juno Therapeutics

Juno Therapeutics Inc
Public
Traded as NASDAQ: JUNO[1]
Industry Biotechnology
Founded 2013[2]
Headquarters Seattle, WA
Key people

Hans Bishop (CEO & President)
Steve Harr, M.D. (CFO)
Hyam Levitsky, M.D. (CSO)

Mark Gilbert, M.D. (CMO)
Website junotherapeutics.com

Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs.[2] The company raised $300 million through private funding and a further $265 million through their IPO.

Company History

In December 2014 the company signed an agreement with Opus Bio, Inc for a chimeric antigen receptor (CAR-T) cell product candidate targeting CD22.[3]

In April 2015 the company entered into a collaboration with MedImmune (a subsidiary of Astra Zeneca) investigating combination treatments for cancer. The trials will assess combinations of MEDI4736 and one of Juno's CD19 directed chimeric antigen receptor T cell candidates.[4] In May 2015, the company announced its intention to acquire Stage Cell Therapeutics for up to $223 million.[5] Later in the same month the company launched a collaboration, with Editas Medicine, to create CAR-T and high-affinity T cell receptor therapies to treat cancer, with the potential to generate up to $737 million-plus for Editas.[6] In June, the company announced it would acquire X-Body for more than $44 million.[7] In June, the company announced a 10-year partnership with Celgene valued at $1 billion.[8] As part of the deal Celgene will pay Juno $150 million and acquire 9.1 million new Juno shares (valued at $93, existing Juno shares rose 26% to $58.38). Celgene will gain the right to sell Juno’s therapies around the world. This partnership surpasses the previous highest record when Pfizer agreed to a deal with Merck KGaA in 2014.[9]

In January 2016 Juno announced it had acquired AbVitro, allowing it to use next-generation single cell sequencing platforms to complement its ability to create T cells engineered to target a broad array of cancer targets.[10] Later in July of the same year, the company announced it would acquire RedoxTherapies for $10 million.[11] In August the company announced it would license rights from Memorial Sloan Kettering Cancer Center and Eureka Therapeutics for a novel, fully human binding domain targeting B-cell maturation antigen.[12]

Pipeline

Drug Notes
JCAR014 Targeted at CD19. Currently in Phase I/II trials at the Fred Hutchison Cancer Research Center, tested for relapsed or refractory chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and acute lymphoblastic leukemia.[13]
JCAR015 Targeted at CD19.[14] Designed to treat acute lymphoblastic leukemia (ALL).
In 2014 in Phase I trials with Memorial Sloan Kettering Cancer Centre; Received Orphan Drug Designation By FDA in November 2014.[15]
In 2016 was in phase II trial for ALL.[14]
JCAR017 Targeted at CD19. Currently in Phase I/II trials at Seattle Children's Hospital, tested for pediatric and young adult relapsed/refractory CD19 positive leukemia.[16]
JTCR016 Targeted at WT-1. Currently in Phase I for adult acute myeloid leukemia.[17]
JCAR023 Targeted at L1CAM. Currently in Phase I for Pediatric neuroblastoma.[17]
JCAR018 Targeted at CD22.Currently in Phase I for non-Hodgkin's lymphoma and acute lymphoblastic leukemia.[17]
others two more in phase I by mid 2016.[17]

References

  1. ↑ "News Release". Juno Therapeutics.
  2. 1 2 "News Release". Juno Therapeutics.
  3. ↑ "News Release". Juno Therapeutics.
  4. ↑ "MedImmune, Juno Team Up to Study Cancer Immunotherapy Combo". GEN.
  5. ↑ "Juno Therapeutics Buys Stage Cell Therapeutics for Up-to-$233M". GEN.
  6. ↑ Staff (May 27, 2015). "Juno, Editas Launch Up-to-$737M+ Cancer Therapy Collaboration". Genetic Engineering & Biotechnology News. Retrieved 2016-02-11.
  7. ↑ "Juno Therapeutics Acquires X-Body for $44M+". GEN.
  8. ↑ "Celgene Launches $1B Immunotherapy Collaboration with Juno". GEN.
  9. ↑ Doni Bloomfield (29 June 2015). "Juno Rises as Celgene Pays $1 Billion to Buy Cancer Stake". Bloomberg.com.
  10. ↑ http://www.genengnews.com/gen-news-highlights/juno-s-abvitro-acquisition-adds-sequencing-to-repertoire/81252218/
  11. ↑ http://www.genengnews.com/gen-news-highlights/juno-buys-redoxtherapies-for-10m/81252959/
  12. ↑ http://www.genengnews.com/gen-news-highlights/juno-licenses-bcma-from-msk-eureka-therapeutics/81253053/
  13. ↑ "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia". clinicaltrials.gov.
  14. 1 2 Juno Seeks Trial Protocol Change Following Patient Deaths. July 2016
  15. ↑ "Juno's JCAR015 Leukemia T Cell Therapy Granted Orphan Drug Designation By FDA". Juno Therapeutics. 18 Nov 2014.
  16. ↑ "A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia". clinicaltrials.gov.
  17. 1 2 3 4 "Pipeline". Juno Therapeutics.
This article is issued from Wikipedia - version of the 10/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.